N. Anthony Coles's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,958 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 1,559 (0%) | 0% | 0 | Common Stock | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 25,000 | 2,177,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 41.18 per share. | 01 Jul 2024 | 25,000 | 25,928 | - | 41.2 | 1,029,535 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 01 Jul 2024 | 25,000 | 50,928 | - | 3.5 | 87,500 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 10,290 | 25,928 | - | - | Common Stock | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 40.61 per share. | 03 Jun 2024 | 50,000 | 15,638 | - | 40.6 | 2,030,520 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 03 Jun 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 50,000 | 2,202,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2024 | 50,000 | 2,252,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 42.10 per share. | 10 May 2024 | 50,000 | 15,638 | - | 42.1 | 2,105,125 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 10 May 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 42.33 per share. | 01 Apr 2024 | 50,000 | 15,638 | - | 42.3 | 2,116,640 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 01 Apr 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 50,000 | 2,302,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 50,000 | 2,352,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 41.01 per share. | 04 Mar 2024 | 50,000 | 15,638 | - | 41.0 | 2,050,550 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 04 Mar 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 50,000 | 2,402,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 41.16 per share. | 29 Feb 2024 | 50,000 | 15,638 | - | 41.2 | 2,057,890 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 29 Feb 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | Anthony N. Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 15,440 | 46,322 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdi... | Coles Anthony N. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 15,440 | 18,144 | - | - | Common Stock | |
| Cerevel Therapeutics Holdi... | Anthony N. Coles | Director | Sale of securities on an exchange or to another person at price $ 41.54 per share. | 06 Feb 2024 | 2,506 | 15,638 | - | 41.5 | 104,110 | Common Stock |
| Cerevel Therapeutics Holdi... | Anthony N. Coles | Director | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 02 Jan 2024 | 50,000 | 2,704 | - | 42.2 | 2,111,815 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Coles Anthony | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 50,000 | 2,452,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | Coles N. Anthony | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 02 Jan 2024 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Regeneron Pharma | Anthony Coles N. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Coles N. Anthony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 1,393 (0%) | 0% | 0 | Common Stock | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 50,000 | 2,702,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 11 Jul 2023 | 50,000 | 2,704 | - | 30.0 | 1,501,340 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 11 Jul 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 32.60 per share. | 01 Jun 2023 | 50,000 | 2,704 | - | 32.6 | 1,630,070 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 50,000 | 2,752,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 01 Jun 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 04 May 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 50,000 | 2,802,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 31.36 per share. | 04 May 2023 | 37,568 | 15,136 | - | 31.4 | 1,178,268 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 31.76 per share. | 04 May 2023 | 12,132 | 3,004 | - | 31.8 | 385,287 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 32.93 per share. | 04 May 2023 | 300 | 2,704 | - | 32.9 | 9,879 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 11 Apr 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 50,000 | 2,852,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 11 Apr 2023 | 50,000 | 2,704 | - | 25.1 | 1,253,130 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 02 Mar 2023 | 47,000 | 49,704 | - | 3.5 | 164,500 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 27.11 per share. | 02 Mar 2023 | 47,000 | 2,704 | - | 27.1 | 1,274,377 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 47,000 | 2,905,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 27.19 per share. | 02 Mar 2023 | 3,000 | 2,704 | - | 27.2 | 81,570 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 02 Mar 2023 | 3,000 | 5,704 | - | 3.5 | 10,500 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 3,000 | 2,902,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 243,042 | 243,042 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 61,762 | 61,762 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 06 Feb 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 50,000 | 2,952,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 33.04 per share. | 06 Feb 2023 | 42,058 | 10,646 | - | 33.0 | 1,389,752 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 33.57 per share. | 06 Feb 2023 | 7,942 | 2,704 | - | 33.6 | 266,649 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 50,000 | 3,002,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 05 Jan 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 29.93 per share. | 05 Jan 2023 | 49,500 | 3,204 | - | 29.9 | 1,481,505 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 30.73 per share. | 05 Jan 2023 | 500 | 2,704 | - | 30.7 | 15,366 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,929 | 1,929 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 165 | 1,258 (0%) | 0% | 0 | Common Stock | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 09 Dec 2022 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 50,000 | 3,052,417 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 26.62 per share. | 09 Dec 2022 | 44,855 | 7,849 | - | 26.6 | 1,193,906 | Common Stock |
| Cerevel Therapeutics Holdi... | N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 09 Dec 2022 | 5,145 | 2,704 | - | 27.1 | 139,395 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2022 | 3,784 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 371.40 per share. | 06 Sep 2022 | 3,784 | 6,793 (0%) | 0% | 371.4 | 1,405,378 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2022 | 2,216 | 2,145 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 06 Sep 2022 | 2,216 | 3,309 (0%) | 0% | 374.1 | 829,050 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 582.56 per share. | 06 Sep 2022 | 1,220 | 2,740 (0%) | 0% | 582.6 | 710,723 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 583.16 per share. | 06 Sep 2022 | 1,045 | 1,695 (0%) | 0% | 583.2 | 609,402 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 581.44 per share. | 06 Sep 2022 | 822 | 3,960 (0%) | 0% | 581.4 | 477,944 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 580.44 per share. | 06 Sep 2022 | 688 | 4,782 (0%) | 0% | 580.4 | 399,343 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 584.57 per share. | 06 Sep 2022 | 602 | 1,093 (0%) | 0% | 584.6 | 351,911 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 579.85 per share. | 06 Sep 2022 | 550 | 5,470 (0%) | 0% | 579.9 | 318,918 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 577.07 per share. | 06 Sep 2022 | 500 | 6,293 (0%) | 0% | 577.1 | 288,535 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 576.73 per share. | 06 Sep 2022 | 300 | 3,009 (0%) | 0% | 576.7 | 173,019 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 578.25 per share. | 06 Sep 2022 | 273 | 6,020 (0%) | 0% | 578.2 | 157,862 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,707 | 2,707 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 191 | 1,093 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2021 | 6,909 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 380.95 per share. | 15 Sep 2021 | 6,909 | 7,811 (0%) | 0% | 381.0 | 2,631,984 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2021 | 5,039 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 345.47 per share. | 15 Sep 2021 | 5,039 | 12,850 (0%) | 0% | 345.5 | 1,740,823 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 661.56 per share. | 15 Sep 2021 | 3,344 | 2,984 (0%) | 0% | 661.6 | 2,212,257 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 656.48 per share. | 15 Sep 2021 | 1,400 | 8,846 (0%) | 0% | 656.5 | 919,072 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 664.32 per share. | 15 Sep 2021 | 1,174 | 902 (0%) | 0% | 664.3 | 779,912 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 652.95 per share. | 15 Sep 2021 | 1,101 | 11,449 (0%) | 0% | 653.0 | 718,898 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 658.65 per share. | 15 Sep 2021 | 935 | 7,076 (0%) | 0% | 658.7 | 615,838 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 663.73 per share. | 15 Sep 2021 | 905 | 2,076 (0%) | 0% | 663.7 | 600,676 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 657.53 per share. | 15 Sep 2021 | 835 | 8,011 (0%) | 0% | 657.5 | 549,038 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 653.31 per share. | 15 Sep 2021 | 800 | 10,649 (0%) | 0% | 653.3 | 522,648 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 660.78 per share. | 15 Sep 2021 | 448 | 6,328 (0%) | 0% | 660.8 | 296,029 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 655.14 per share. | 15 Sep 2021 | 403 | 10,246 (0%) | 0% | 655.1 | 264,021 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 659.00 per share. | 15 Sep 2021 | 300 | 6,776 (0%) | 0% | 659 | 197,700 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 651.36 per share. | 15 Sep 2021 | 300 | 12,550 (0%) | 0% | 651.4 | 195,408 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 662.67 per share. | 15 Sep 2021 | 3 | 2,981 (0%) | 0% | 662.7 | 1,988 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 5,100 | 5,039 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 650.00 per share. | 17 Aug 2021 | 5,100 | 902 (0%) | 0% | 650 | 3,315,000 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 345.47 per share. | 17 Aug 2021 | 5,100 | 6,002 (0%) | 0% | 345.5 | 1,761,897 | Common Stock |
| Regeneron Pharma | N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 900 | 10,139 | - | - | Non-Qualified Stock Option (right to buy) |